Skip to main content

Table 6 Summary of drug-related adverse events during the maintenance period

From: Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China

 

Lanthanum carbonate (n=115)

Placebo (n=115)

Symptoms

Cases

Number

Incidence

Cases

Number

Incidence

Nausea

12

8

6.96%

 

0

 

Vomiting

11

7

6.09%

 

0

 

Constipation

 

0

 

1

1

0.87%

Anorexia

1

1

0.87%

 

0

 

Hypocalcemia

 

0

 

1

1

0.87%

Aggravated itching

 

0

 

1

1

0.87%

Total

24

16

13.91%

3

3

2.61%